Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma

References

• Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013;19:760–766.
   PubMed Web of Science ®Google Scholar
• Cook G, Williams C, Brown JM, et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation [NCRI Myeloma X Relapse [Intensive trial]]: a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:874–885.
   PubMed Web of Science ®Google Scholar
• Awan F, Kochuparambil ST, Falconer DE, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant. 2013;48:1279–1284.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. 3102 Investigators plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• Li J, Hamilton E, Vaughn L, et al. Effectiveness and cost analysis of “just-in-time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011;51:2175–2182.
   PubMed Web of Science ®Google Scholar
• Chabannon C, Bijou F, Miclea JM, et al. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on-demand” scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion. 2015;55:2149–2157.
   PubMed Web of Science ®Google Scholar
• D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011;46:356–363.
   PubMed Web of Science ®Google Scholar
• Chow E, Rao KV, Wood WA, et al. Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization. Biol Blood Marrow Transplant. 2014;20:1064–1068.
   PubMed Web of Science ®Google Scholar
• Attolico I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 2012;18:241–249.
   PubMed Web of Science ®Google Scholar
• Milone G, Tripepi G, Martino M, et al. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding “on demand” use of plerixafor. Blood Transfus. 2013;11:94–101.
   PubMed Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol. 2014;164:113–123.
   PubMed Web of Science ®Google Scholar
• Chabannon C, Le Corroller AG, Viret F, et al. Cost-effectiveness of repeated aphereses in poor mobilizers undergoinghigh-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia. 2003;17:811–820.
   PubMed Web of Science ®Google Scholar
• Clark RE, Bell J, Clark JO, et al. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Blood Cancer J. 2014;4:e255.
   PubMed Web of Science ®Google Scholar
• Costa LJ, AN, Alexander ET, Hogan KR, et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant. 2011;46:523–528.
   PubMed Web of Science ®Google Scholar
• Abhyankar S, DeJarnette S, Aljitawi O, et al. A risk based approach to optimize autologous hematopoietic stem cell [HSC] collection with the use of plerixafor. Bone Marrow Transplant. 2012;47:483–487.
   PubMed Web of Science ®Google Scholar
• Abusin GA, Abu-Arja RF, Gingrich RD, et al. An algorithm for utilizing peripheral blood CD34 count as a predictor of the need for plerixafor in autologous stem cell mobilization – cost-effectiveness analysis. J Clin Apher. 2013;28:293–300.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013;19:87–93.
   PubMed Web of Science ®Google Scholar
• Gojo I, Guo C, Sarkodee-Adoo C, et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant. 2004;34:69–76.
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant. 2001;27:837–842.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Kochuparambil ST, Osman S, et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant. 2012;18:1128–1135.
   PubMed Web of Science ®Google Scholar
• Lerro KA, Medoff E, Wu Y, et al. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant. 2003;32:1113–1117.
   PubMed Web of Science ®Google Scholar
• Silvennoinen R, Anttila P, Säily M, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide + G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant. 2016;51:372–376.
   PubMed Web of Science ®Google Scholar